Pulmonary type-2 innate lymphoid cells in paediatric severe asthma: phenotype and response to steroids.
Adolescent
Asthma
/ physiopathology
Child
Eosinophils
/ immunology
Female
Humans
Immunity, Innate
Immunophenotyping
Interleukin-13
/ metabolism
Interleukin-17
/ metabolism
Leukocytes
/ immunology
Leukocytes, Mononuclear
/ immunology
Lung
Lymphocytes
/ immunology
Male
Pediatrics
Phenotype
Steroids
/ therapeutic use
Th17 Cells
/ immunology
Th2 Cells
/ immunology
Triamcinolone
/ therapeutic use
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
26
09
2018
accepted:
26
05
2019
pubmed:
6
6
2019
medline:
30
9
2020
entrez:
6
6
2019
Statut:
epublish
Résumé
Children with severe therapy-resistant asthma (STRA) have poor control despite maximal treatment, while those with difficult asthma (DA) have poor control from failure to implement basic management, including adherence to therapy. Although recognised as clinically distinct, the airway molecular phenotype, including the role of innate lymphoid cells (ILCs) and their response to steroids in DA and STRA is unknown.Immunophenotyping of sputum and blood ILCs and T-cells from STRA, DA and non-asthmatic controls was undertaken. Leukocytes were analysed longitudinally pre- and post-intramuscular triamcinolone in children with STRA. Cultured ILCs were evaluated to assess steroid responsiveness
Identifiants
pubmed: 31164437
pii: 13993003.01809-2018
doi: 10.1183/13993003.01809-2018
pmc: PMC6713888
pii:
doi:
Substances chimiques
IL17A protein, human
0
Interleukin-13
0
Interleukin-17
0
Steroids
0
Triamcinolone
1ZK20VI6TY
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 107059/Z/15/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright ©ERS 2019.
Déclaration de conflit d'intérêts
Conflict of interest: F. Puttur has nothing to disclose. Conflict of interest: L.G. Gregory has nothing to disclose. Conflict of interest: L. Denney has nothing to disclose. Conflict of interest: L. Fleming reports other funding from GSK, Sanofi, Novartis, Boehrringer Ingelheim and Astra Zeneca, outside the submitted work. Conflict of interest: A. Bush has nothing to disclose. Conflict of interest: C.M. Lloyd has nothing to disclose. Conflict of interest: S. Saglani has nothing to disclose. Conflict of interest: P. Nagakumar has nothing to disclose.
Références
J Allergy Clin Immunol. 2001 Sep;108(3):430-8
pubmed: 11544464
J Immunol. 2002 Jul 1;169(1):443-53
pubmed: 12077275
Chest. 2010 Nov;138(5):1140-7
pubmed: 20538817
Lancet. 2010 Sep 4;376(9743):814-25
pubmed: 20816548
Nat Immunol. 2011 Jan;12(1):21-7
pubmed: 21113163
Am J Respir Crit Care Med. 2011 Jul 15;184(2):252-8
pubmed: 21474644
Nat Immunol. 2011 Sep 11;12(11):1055-62
pubmed: 21909091
Thorax. 2012 Feb;67(2):164-70
pubmed: 22008188
J Allergy Clin Immunol. 2012 Jan;129(1):216-27.e1-6
pubmed: 22119406
J Allergy Clin Immunol. 2012 Apr;129(4):974-82.e13
pubmed: 22385633
Eur Respir J. 2012 Jul;40(1):264-7
pubmed: 22753835
Allergy. 2013 Mar;68(3):402-6
pubmed: 23347007
J Allergy Clin Immunol. 2013 Sep;132(3):676-685.e13
pubmed: 23759184
J Allergy Clin Immunol. 2013 Oct;132(4):933-41
pubmed: 23810766
Nat Med. 2013 Aug;19(8):977-9
pubmed: 23921745
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Thorax. 2014 Jun;69(6):508-15
pubmed: 24347461
Am J Respir Crit Care Med. 2014 Nov 15;190(10):1094-101
pubmed: 25162311
Clin Immunol. 2014 Nov;155(1):126-35
pubmed: 25236785
Eur Respir J. 2014 Nov;44(5):1378-9
pubmed: 25362128
Nat Rev Immunol. 2015 Jan;15(1):57-65
pubmed: 25534623
J Allergy Clin Immunol. 2015 Aug;136(2):312-22.e7
pubmed: 25746970
Curr Opin Immunol. 2015 Jun;34:99-106
pubmed: 25794823
J Allergy Clin Immunol. 2016 Jan;137(1):75-86.e8
pubmed: 26194544
J Allergy Clin Immunol. 2016 Feb;137(2):624-626.e6
pubmed: 26277593
J Allergy Clin Immunol. 2016 Aug;138(2):413-420.e6
pubmed: 27061250
Nat Immunol. 2016 Jun;17(6):626-35
pubmed: 27111143
J Allergy Clin Immunol. 2016 Nov;138(5):1309-1318.e11
pubmed: 27177781
J Allergy Clin Immunol. 2017 Apr;139(4):1167-1175.e2
pubmed: 27726946
J Allergy Clin Immunol. 2017 Jun;139(6):1819-1829.e11
pubmed: 27746241
J Allergy Clin Immunol. 2016 Dec;138(6):1608-1618.e12
pubmed: 27777180
Am J Respir Crit Care Med. 2017 Sep 15;196(6):700-712
pubmed: 28422515
J Allergy Clin Immunol. 2018 Jan;141(1):257-268.e6
pubmed: 28433687
Respirology. 2017 Jul;22(5):886-897
pubmed: 28543931
Clin Rev Allergy Immunol. 2018 Feb;54(1):114-130
pubmed: 28688013
J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):901-908
pubmed: 28689840
Lancet Respir Med. 2017 Nov;5(11):844-846
pubmed: 29031948
Clin Exp Allergy. 2018 Mar;48(3):241-252
pubmed: 29315966
Eur J Immunol. 2019 Jan;49(1):144-156
pubmed: 29762870